MORE VIDEOS
Explore more

Pulmonary Inflammatory Myofibroblastic Tumor

Pursue 12 N (Uploaded): Interesting case series in Respiratory Pathology – : Session 1
Pursue 12 N (Uploaded): Interesting case series in Respiratory Pathology – : Session 1 administrator 21 Views • 2 years ago

Pursue 12 N (Live): RESPIRATORY SYSTEM :
Interesting case series in Respiratory Pathology – National perspective : Session 1


Lecture conducted by:
Dr Deepali Jain, MD, DNB, FIAC
Additional Professor, Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Multiple publications in indexed national and international Journals
resection of pulmonary artery sarcoma using cardiopulmonary bypass
resection of pulmonary artery sarcoma using cardiopulmonary bypass administrator 14 Views • 2 years ago

En bloc resection pulmonary artery sarcoma was possible under cardiopulmonary bypass support. (presented in 2015 ESTS meeting)
Dr. Andre Goy on Crizotinib for ALK-positive Pediatric Patients With ALCL
Dr. Andre Goy on Crizotinib for ALK-positive Pediatric Patients With ALCL administrator 3 Views • 2 years ago

Andre Goy, MD, MS, chief, Lymphoma Division, chairman, John Theurer Cancer Center at Hackensack University Medical Center, discusses a small phase I trial that used crizotinib (Xalkori) to treat ALK-positive pediatric patients with anaplastic large cell lymphoma (ALCL), neuroblastoma, and inflammatory myofibroblastic tumors (IMTs).

View more at http://www.onclive.com/confere....nce-coverage/asco-20

Is this inflammatory pseudotumor or intrahepatic cholangiocarcinoma (CCA)?
Is this inflammatory pseudotumor or intrahepatic cholangiocarcinoma (CCA)? administrator 3 Views • 2 years ago

inflammatory myofibroblastic tumor of stomach
inflammatory myofibroblastic tumor of stomach administrator 6 Views • 2 years ago

this rare tumor found on routine gastroscopy for gi blood loss with malena . patient was not presented with hematemesis.12x15 cms size with episodes of dropping of Hb .pt was having large pedunculated tumor with firm consistency with no s/o friability & was operated by gastrotomy with ligation of pedicle with complete hemostasis as there is enough pedicle to ligate with safe margin . pathological diagnosis was inflammatory myofibroblastic tumor of stomach. patient is under follow up
Lung Pathology (Lung Tumors) - Dr. Sigdel
Lung Pathology (Lung Tumors) - Dr. Sigdel administrator 4 Views • 2 years ago

Inflammatory Myofibroblastic Tumors in Paranasal Sinus and Nasopharynx
Inflammatory Myofibroblastic Tumors in Paranasal Sinus and Nasopharynx administrator 5 Views • 2 years ago

Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,
https://plus.google.com/communities/1...
,
,https://plus.google.com/u/0/+Alexandr...
,
https://www.youtube.com/channel/UCQH2...
,
https://www.youtube.com/channel/UCTRE...
,
https://twitter.com/g_orl?lang=el,
https://www.instagram.com/alexandross...,


: A Clinical Retrospective Study of 13 Cases
via BioMed Research International
Background. Inflammatory myofibroblastic tumor (IMT), as a mesenchymal tumor, is common in the lung and abdomen but rare in the paranasal sinus and nasopharynx. Objective. This study aimed to summarize the clinical characteristics of IMT in the paranasal sinus and nasopharynx and analyze the relationship between the treatment and the overall survival (OS). Method. The clinical features, treatment, and follow-up data of patients diagnosed with IMT of the paranasal sinus or nasopharynx from 2006 to 2017 were retrospectively analyzed, and the previous literature was reviewed. Results. IMT often presents as an ill-defined soft-tissue mass with bone destruction and invasion of surrounding structures. The treatment methods used in this study were different combinations of surgery, prednisone, radiotherapy, and chemotherapy or observation alone. Three of the 13 patients were lost and the follow-up time of the remaining 10 cases ranged from 2 to 87 months (median, 39 months). Two patients died of the disease; the other eight patients were stable. The 5-year survival rate was 72%. Among the four methods of treatment, only treatment with prednisone was significantly correlated with better OS (P = 0.046). Conclusions. IMT is an intermediate tumor that often mimics malignancy. We are not sure if IMTs in the nasal cavity are more aggressive because of the biology or if the location and local therapy in the head region is more complicated. Radiologic findings help know the extent of the lesion. For unresectable nasal IMT, combined therapy with glucocorticoids, chemotherapy, and radiotherapy is sometimes a better choice. Glucocorticoids are especially recommended as a basic part of the integrated therapy. However, the standard treatment needs further research.
Add tags (Currently: Biomedical Engineering, #MedicinebyAlexandrosSfakianakis, # Ola by Sfakianakis G. Alexandros)

ALK and ROS1 in Lung Cancer Next Generation Targeted Therapies
ALK and ROS1 in Lung Cancer Next Generation Targeted Therapies administrator 2 Views • 2 years ago

Alice T. Shaw, MD, PhD
Refinement of diagnosis and supporting evidence for use of immunotherapy- Video Abstract ID 203192
Refinement of diagnosis and supporting evidence for use of immunotherapy- Video Abstract ID 203192 administrator 4 Views • 2 years ago

Video abstract of case report “Refinement of diagnosis and supporting evidence for use of immunotherapy through sequential biopsies in a case of EML4-ALK positive lung cancer” published in the open access journal OncoTargets and Therapy by Song P, Zhang J, Zhang L.

Abstract: In this case report, we describe a tortuous, yet rare, treatment process of the patient. The first biopsy of the patient suggested inflammatory myofibroblastic tumor, ALK (D5F3) positive. Considering the benign progression of the disease, and no indication for surgical resection, oral prednisone was given first. However, the disease rapidly progressed, and a second biopsy revealed a pulmonary sarcomatoid cancer. Since the biopsy was ALK (D5F3) positive, the effect of crizotinib treatment was significant, though crizotinib resistance unfortunately only occurred after 4 months. The third biopsy pathology was performed and confirmed lung adenocarcinoma. After switching to pembrolizumab treatment, the lesions were significantly reduced after four courses of treatment. The current condition of patient persisted in partial response.

Read the full paper here https://www.dovepress.com/refi....nement-of-diagnosis-

STR Cardiothoracic Case Webinar 6/25/2020
STR Cardiothoracic Case Webinar 6/25/2020 administrator 2 Views • 2 years ago

00:15 - extremely large malignant phyllodes tumor of the breast
1:34 - silicone leakage from breast implant into pleural space following sympathetic ganglion surgery
5:24 - presumed pulmonary capillary hemangiomatosis
12:02 - endocardial fibroelastosis in patient with history of coarctation of aorta and Wolff-Parkinson-White syndrome
15:50 - cardiac paraganglioma vs. angiosarcoma
20:19 - IVC intramural hematoma
22:51 - pulmonary hemorrhage from cocaine inhalation
24:36 - malignant metastatic germ cell tumor in mediastinum in patient with Klinefelter syndrome
26:40 - pleuroparenchymal fibroelastosis
29:02 - pulmonary adenocarcinoma with secondary micropapillary component and visceral pleural involvement
31:50 - rapidly progressing fibrosis in patient with ANCA-associated vasculitis
34:08 - another case of rapidly fibrosis in patient with Sjogren syndrome
36:43 - STAT-6 positive solitary fibrous tumor
38:22 - inflammatory myofibroblastic tumor with ALK rearrangement presenting as incidental lung nodule
40:35 - intra-tracheal metastasis from clear cell renal cancer
41:10 - interstitial fibrosing lung disorder that is hard to classify; indeterminate for UIP
49:28 - pseudoaneurysm on right inferior epigastric artery following cardiac catheterization
50:32- abscess cavities seen in infected aortic root
52:53 - transseptal course of anomalous left main coronary artery

Time stamps courtesy of Matthew Pavlica, NYITCOM
Showing 10 out of 11